S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News

$6.39
+0.04 (+0.63 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$6.18
Now: $6.39
$6.45
50-Day Range
$3.16
MA: $4.58
$6.42
52-Week Range
$2.99
Now: $6.39
$9.30
Volume1.25 million shs
Average Volume1.13 million shs
Market Capitalization$760.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$207.74 million
Book Value$5.44 per share

Profitability

Net Income$-143,590,000.00

Miscellaneous

Employees324
Market Cap$760.05 million
Next Earnings Date3/24/2020 (Estimated)
OptionableOptionable

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.


Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. The biopharmaceutical company had revenue of $91.98 million for the quarter, compared to the consensus estimate of $93.94 million. Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

5 equities research analysts have issued 12 month price objectives for Akebia Therapeutics' shares. Their forecasts range from $9.00 to $17.00. On average, they expect Akebia Therapeutics' stock price to reach $13.80 in the next year. This suggests a possible upside of 116.0% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

What is the consensus analysts' recommendation for Akebia Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/21/2019)
  • 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019)

Has Akebia Therapeutics been receiving favorable news coverage?

News headlines about AKBA stock have trended neutral this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akebia Therapeutics earned a news impact score of 0.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Akebia Therapeutics.

Who are some of Akebia Therapeutics' key competitors?

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Energy Transfer LP Unit (ET), FireEye (FEYE), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Bank of America (BAC), Netflix (NFLX) and Ford Motor (F).

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)
  • Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
  • Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
  • Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)
  • Mr. Douglas Jermasek, VP of Marketing & Strategy

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.07%), Point72 Asset Management L.P. (1.49%), Rice Hall James & Associates LLC (1.25%), Man Group plc (0.31%), Massachusetts Financial Services Co. MA (0.29%) and Boston Partners (0.25%). Company insiders that own Akebia Therapeutics stock include Duane Nash, John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics.

Which major investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, Millennium Management LLC, Squarepoint Ops LLC, Rice Hall James & Associates LLC and Metropolitan Life Insurance Co NY. View Insider Buying and Selling for Akebia Therapeutics.

Which major investors are buying Akebia Therapeutics stock?

AKBA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Boston Partners, Massachusetts Financial Services Co. MA, California Public Employees Retirement System, Virginia Retirement Systems ET AL, Virtu Financial LLC, Rhumbline Advisers and SG Americas Securities LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $6.39.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $760.05 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.

What is Akebia Therapeutics' official website?

The official website for Akebia Therapeutics is http://www.akebia.com/.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]


MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  281 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel